February 24, 2017 / 12:26 PM / 9 months ago

BRIEF-EU regulator recommends condition approval of Shire's chronic hypoparathyroidism medicine

Feb 24 (Reuters) - EU Medicines Agency:

* Recommendations for February 2017

* Recommends conditional marketing authorisation of Shire’s orphan medicine Natpar for chronic hypoparathyroidism

* Recommends approval of Astrazeneca’s ZS-9 (sodium zirconium cyclosilicate) for high potassium levels

* Recommends approval of Tesaro Inc’s rolapitant, against chemotherapy-induced nausea and vomiting

* Recommends approval of Gilead's Descovy for the treatment of HIV Link to press release: (bit.ly/2lCHPks) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below